Literature DB >> 7820141

Size and status of metastases after inductive chemotherapy of germ-cell tumors. Indication for salvage operation.

N Jaeger1, L Weissbach, R Bussar-Maatz.   

Abstract

Secondary resection of metastases remaining after inductive chemotherapy of advanced germ-cell tumors has thus far been obligatory. The absence of malignant components in one-third of all residual tumors and the high risk of the operation have led several authors to reconsider the criteria for this approach. In a retrospective study of 153 cases (127 evaluable) we investigated the histology of the primary tumor and the size of the residual tumor with regard to residual histology and outcome. Patients were divided into the following three groups according to the histology of the primary tumor: group I, pure seminoma (16 patients); group II, nonseminoma without teratoma (32 patients); and group III, nonseminoma with teratoma (79 patients). Among the 16 purely seminomatous tumors, the residual masses ranged from 2 to 12 cm; 12 consisted of necrotic tissue only, 3 contained malignant germ-cell elements, and 1 contained adult teratoma. The residuals of primarily teratoma-free nonseminomas measured 2-16 cm; the smallest residual tumor containing active malignant elements measured 4 cm, and the diameter of the largest necrotic residue was 6 cm. Four residuals contained mature teratoma. The size of residuals from teratomatous primary tumors was 3-24 cm; the smallest malignant tumor measured 5 cm, and the diameter of the largest purely necrotic mass was 8 cm. According to our results, a secondary operation may be omitted if the residual mass of a primary seminoma is smaller than 5 cm or if that of a primary nonseminoma without teratoma is less than 3 cm in diameter.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7820141     DOI: 10.1007/bf00185673

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  25 in total

1.  The role of surgery in the combined management of metastases from malignant teratomas of testis.

Authors:  W F Hendry; P Goldstraw; M J Peckham
Journal:  Br J Urol       Date:  1987-04

2.  Non-seminomatous germ cell tumors of the testis: morphology of retroperitoneal lymph node metastases after chemotherapy.

Authors:  A J Suurmeijer; J W Oosterhuis; D T Sleijfer; H S Koops; G J Fleuren
Journal:  Eur J Cancer Clin Oncol       Date:  1984-06

3.  The management of advanced seminoma.

Authors:  J N Wettlaufer
Journal:  Semin Urol       Date:  1984-11

4.  Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer.

Authors:  J P Donohue; R G Rowland; K Kopecky; C P Steidle; G Geier; K G Ney; L Einhorn; S Williams; P Loehrer
Journal:  J Urol       Date:  1987-06       Impact factor: 7.450

5.  Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.

Authors:  D P Wood; H W Herr; R J Motzer; V Reuter; P C Sogani; M J Morse; G J Bosl
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

6.  Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy.

Authors:  F H Dexeus; A Shirkhoda; C J Logothetis; C Chong; A Sella; S Ogden; D Swanson
Journal:  Eur J Cancer Clin Oncol       Date:  1989-01

7.  Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors.

Authors:  J N Wettlaufer; A S Feiner; W A Robinson
Journal:  Cancer       Date:  1984-01-15       Impact factor: 6.860

8.  Chemotherapy of disseminated testicular cancer. A random prospective study.

Authors:  L H Einhorn; S D Williams
Journal:  Cancer       Date:  1980-09-15       Impact factor: 6.860

9.  Vinblastine, actinomycin D, bleomycin, cyclophosphamide and cis-platinum combination chemotherapy in metastatic testis cancer--a 1-year program.

Authors:  D Vugrin; W F Whitmore; R B Golbey
Journal:  J Urol       Date:  1982-12       Impact factor: 7.450

10.  The growing teratoma syndrome: an unusual manifestation of treated, nonseminomatous germ cell tumors of the testis.

Authors:  J G Lorigan; F Eftekhari; C L David; A Shirkhoda
Journal:  AJR Am J Roentgenol       Date:  1988-08       Impact factor: 3.959

View more
  3 in total

Review 1.  Imaging of abdominal nodal spread in malignant disease.

Authors:  S Delorme; G van Kaick
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

2.  [Regression of germ cell tumors after chemotherapy].

Authors:  V Loy; U Klenk; J Linke
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

3.  Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours.

Authors:  M P Napier; A Naraghi; T J Christmas; G J Rustin
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.